胆固醇干扰导致大脑小血管疾病中的运动认知功能障碍
Mengfei Cai1,2,3, Hao Li3, Milan Nemy4,5
1Guangdong Cardiovascular Institute (M.C.), Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Stroke
|October 30, 2025
概括
小血管疾病 (SVD) 与认知能力下降和步态问题有关. 大脑中的干扰.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 放射学 放射学是一门学科.
背景情况:
- 小血管疾病 (SVD) 经常导致同时的认知衰退和步态障碍,这种情况被称为运动认知功能障碍.
- 胆固醇系统中断在SVD患者运动认知功能障碍的发展中的具体作用尚不清楚.
研究的目的:
- 在患有小血管疾病 (SVD) 的患者中调查胆能通路干扰和运动认知功能障碍之间的关联.
- 为了确定SVD中白质过强度 (WMH) 是否会影响特定的胆固醇通路.
主要方法:
- 一项横截面研究包括213名SVD患者进行多式核磁共振,步态测试 (6米步行测试) 和认知评估.
- 使用概率曲谱来重建和量化胆能皮质和胸膜通路中的干扰,使用神经元定向分散和密度成像 (NODDI) 的扩散指标.
- 使用了调整为SVD标记物和白质NODDI指标的线性回归模型.
主要成果:
- 白质超强度 (WMH) 与中断的胆能通路有显著的关联,特别是在外部囊内.
- 外部囊和环膜胆固醇通路的干扰与认知表现和步态的同时下降相关.
- 外部囊胆固醇通路内的WMH与通道中断的关联比总WMH体积更强.
结论:
- 胆固醇皮质通路的干扰,特别是外部囊和带膜,与SVD患者的运动认知功能障碍有关.
- 这些发现表明,与SVD相关的皮质胆性通路的损伤,而不是thalamic通路,是运动认知功能障碍的关键因素.
相关概念视频
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
535
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
535
Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.2K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.5K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.5K
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.8K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.8K
Cholinergic Antagonists: Pharmacological Actions
1.6K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.6K


